Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
With a slashed valuation the newly listed biotech heads for phase 3.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
An actinium-based backup and Werner helicase inhibitor are notable absences.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
